Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2025-07-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2025
Regulatory Filings Classification · 78% confidence The document is a “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed with HKEX under its Listing Rules (Chapter 19B and Main Board Rule 13.25C/GEM Rule 17.27C). It details monthly movements in authorised share capital, issued shares, share options, convertibles, etc. It is not an earnings release, interim/annual report, or a specific transaction announcement (e.g., buyback or major fundraising). Rather, it is a standard regulatory filing to the exchange summarising monthly share capital movements. This does not fit specialized categories like ER, IR, SHA, or POS, but instead falls under the general “Regulatory Filings” (RNS) fallback category.
2025-07-03 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 85% confidence The document is a formal announcement listing the current board members, their roles and committee memberships. There is no mention of appointments, resignations or changes; rather, it describes the governance structure (board composition and committee memberships) in line with listing rule disclosures. This aligns with a Governance Information filing, not a change announcement or meeting materials.
2025-06-26 English
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE
Governance Information Classification · 95% confidence The document contains the Terms of Reference for the Nomination Committee of the Board, detailing committee composition, purpose, meetings, authorities, responsibilities, and governance procedures. This is a corporate governance internal rules document rather than a financial report or announcement. Therefore, it falls under Governance Information (Code: CGR).
2025-06-26 English
APPOINTMENT OF DIRECTORS
Board/Management Information Classification · 95% confidence The document is an official Hong Kong Stock Exchange announcement regarding the appointment of three new directors to the company’s board, describing their backgrounds, terms, and compliance with listing rules. This fits squarely under Board/Management Information (announcement of changes in board of directors or senior management).
2025-06-26 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 88% confidence The document is a formal announcement filed on the Hong Kong Stock Exchange disclosing the company’s full board composition and committee membership. It contains no narrative on financial results, capital changes, votes, or appointments/changes—it simply lists governance structures and roles. This aligns with the “Governance Information” category (CGR), which covers reports on board structure and governance practices.
2025-06-25 English
SUPPLEMENTAL ANNOUNCEMENT RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHIEF TECHNOLOGY OFFICER
Board/Management Information Classification · 90% confidence The text is a corporate announcement providing supplemental details on the resignation of the company’s Executive Director, CEO, and CTO and discussing board governance matters. It clearly relates to changes in the company’s board/senior management rather than an earnings release or regulatory filing. Therefore, it falls under Board/Management Information (MANG).
2025-06-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.